Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes (Q38005622)

26 August 2017

title

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes (English)

1 reference

26 August 2017

1 reference

4

1 reference

26 August 2017

Alexander C Small

2

0 references

author name string

Matthew D Galsky

series ordinal

1

1 reference

26 August 2017

Che-kai Tsao

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

24 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

62

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

299-308

1 reference

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

The development of differentiation agents for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

The role of RANK-ligand inhibition in cancer: the story of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Radioisotopic treatment of bone pain from metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21141

21 January 2018

Identifiers

DOI

10.3322/CAAC.21141

1 reference

26 August 2017

1 reference